Dr Audrey Kong Presents Continuous Ketone Monitoring Case Study at ATTD Asia 2025
We’d like to congratulate Dr Audrey Kong for her presentation at ATTD ASIA 2025. Dr Kong’s presentation focused on a case study using continuous ketone monitoring technology to detect and prevent diabetic keto-acidosis (DKA), an emerging field in diabetes technology research.
Preventing diabetic ketoacidosis (DKA) is a key component of type 1 diabetes management. However, identification of impending DKA requires ketone strip availability and timely user initiation of ketone testing, which often does not occur. Continuous ketone monitoring (CKM) may improve recognition and management of impending DKA.
This case study focused on a 55-year-old male with type 1 diabetes for 53 years and undetectable C-peptide levels, with excellent glycaemic management (HbA1c 6.9% [51.9 mmol/mol]; continuous glucose monitor [CGM] time-in-range [3.9-10 mmol/L] 83%, time-above-range [>10 mmol/L] 14%, time-below-range [<3.9 mmol/L] 3%) on an automated insulin delivery system comprising of a tubed insulin pump. His last episode of DKA was during childhood. As part of a clinical trial (ACTRN12624000448549), he wore a CKM (Abbott) and received education in responding to ketone information.
During a 2.5 hour gap in CGM data due to sensor warm-up, he experienced a rapid rise in ketone levels from 0.6 mmol/L to >3.1 mmol/L due to insulin pump cannula dislodgement. Glucose levels peaked at 17.8 mmol/L. The first indication of insulin insufficiency was a CKM alarm notification of elevated ketones >1.0 mmol/L, which prompted recognition of the issue and treatment of ketonemia by replacing the cannula and administering additional insulin. Ketonemia resolved without hospital attendance. He was asymptomatic throughout.
This case study suggests that CKM can facilitate early recognition of pump insulin delivery failure and act as an early warning system to enable timely recognition and intervention for impending DKA, which can reduce DKA and hospital presentation/admission.
Dr Audrey Kong Presents Continuous Ketone Case Study at ATTD Asia 2025
We’d like to congratulate Dr Audrey Kong for her presentation at ATTD ASIA 2025. Dr Kong’s presentation focused on a case study using continuous ketone monitoring technology to detect and prevent diabetic keto-acidosis (DKA), an emerging field in diabetes technology research.
Preventing diabetic ketoacidosis (DKA) is a key component of type 1 diabetes management. However, identification of impending DKA requires ketone strip availability and timely user initiation of ketone testing, which often does not occur. Continuous ketone monitoring (CKM) may improve recognition and management of impending DKA.
This case study focused on a 55-year-old male with type 1 diabetes for 53 years and undetectable C-peptide levels, with excellent glycaemic management (HbA1c 6.9% [51.9 mmol/mol]; continuous glucose monitor [CGM] time-in-range [3.9-10 mmol/L] 83%, time-above-range [>10 mmol/L] 14%, time-below-range [<3.9 mmol/L] 3%) on an automated insulin delivery system comprising of a tubed insulin pump. His last episode of DKA was during childhood. As part of a clinical trial (ACTRN12624000448549), he wore a CKM (Abbott) and received education in responding to ketone information.
During a 2.5 hour gap in CGM data due to sensor warm-up, he experienced a rapid rise in ketone levels from 0.6 mmol/L to >3.1 mmol/L due to insulin pump cannula dislodgement. Glucose levels peaked at 17.8 mmol/L. The first indication of insulin insufficiency was a CKM alarm notification of elevated ketones >1.0 mmol/L, which prompted recognition of the issue and treatment of ketonemia by replacing the cannula and administering additional insulin. Ketonemia resolved without hospital attendance. He was asymptomatic throughout.
This case study suggests that CKM can facilitate early recognition of pump insulin delivery failure and act as an early warning system to enable timely recognition and intervention for impending DKA, which can reduce DKA and hospital presentation/admission.